Please login to the form below

Not currently logged in
Email:
Password:

hyperkalaemia

This page shows the latest hyperkalaemia news and features for those working in and with pharma, biotech and healthcare.

NICE says no to AZ and Vifor’s rival hyperkalaemia drugs

NICE says no to AZ and Vifor’s rival hyperkalaemia drugs

Between 1% and 10% of hospital inpatients have hyperkalaemia. Many patients won’t display any symptoms, but some severe cases can lead to cardiac arrest. ... Hyperkalaemia is also seen in patients taking common medications for heart failure, such as

Latest news

More from news
Approximately 5 fully matching, plus 8 partially matching documents found.

Latest Intelligence

  • AstraZeneca’s focus on diagnosing and managing chronic kidney disease AstraZeneca’s focus on diagnosing and managing chronic kidney disease

    Hyperkalaemia (elevated levels of potassium in the blood) and anaemia are both common complications of CKD, associated with poorer cardiovascular outcomes and an increased risk of hospitalisation and death. ... For instance, we are exploring patient

  • Deal Watch July 2016 Deal Watch July 2016

    for the treatment of hyperkalaemia.

  • Deal Watch November 2015 Deal Watch November 2015

    Paying $90 per share (headline value $2.7bn) in acquiring ZS Pharma, AstraZeneca gains access to ZS-9, a possible best in class product for hyperkalaemia which is under FDA review. ... ZS Pharma. AstraZeneca. Acquisition - company. Lead product ZS-9,

  • Pharma deals during October 2013 Pharma deals during October 2013

    Examples of recent IPOS. Company. Product/technology. Target ($m). Relypsa. Patiromer for hyperkalaemia in chronic kidney disease (phase III).

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Visformatics (VISFO)

A team of strategic decision specialists with over 30+ years in the pharma space, we give you confidence through experience....

Latest intelligence

Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
Employee wellbeing in creative agencies: three tips to get you started
Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
Managing unhelpful pressure in your creative agency: the human approach
Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...